ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.478,19
-0,66%
S&P 500
5.653,11
0,39%
Dow Jones
40.559,32
0,86%
Euro vs US Dollar
1,08796
-0,18%
Bitcoin
63.822,19
-1,59%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
17/09/202200h23Dow Jones NewsADRs End Lower, ArcelorMittal and AstraZeneca Trade ActivelyNASDAQ:AZNAstraZeneca PLC
16/09/202213h10Business WireDanicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular HemolysisNASDAQ:AZNAstraZeneca PLC
16/09/202212h51Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
16/09/202212h41Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
16/09/202212h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
16/09/202208h53Dow Jones NewsAstraZeneca's Covid-19 Treatment Evusheld Recommended for Authorization in the European UnionNASDAQ:AZNAstraZeneca PLC
16/09/202208h53Dow Jones NewsAstraZeneca Says Danicopan Met Primary Endpoint in Phase 3 TrialNASDAQ:AZNAstraZeneca PLC
16/09/202208h45Dow Jones NewsAstraZeneca Says Nirsevimab Recommended for Approval in EUNASDAQ:AZNAstraZeneca PLC
15/09/202218h40Business WireAstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19NASDAQ:AZNAstraZeneca PLC
15/09/202218h00Business WireAstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19NASDAQ:AZNAstraZeneca PLC
12/09/202217h05Business WireIMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-upNASDAQ:AZNAstraZeneca PLC
11/09/202215h35Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung CancerNASDAQ:AZNAstraZeneca PLC
11/09/202214h05Business WireIMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapyNASDAQ:AZNAstraZeneca PLC
11/09/202214h00Business WireTAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancerNASDAQ:AZNAstraZeneca PLC
09/09/202215h11Dow Jones NewsAstraZeneca, Merck Say Lynparza Trial Shows Long-Term Survival IncreaseNASDAQ:AZNAstraZeneca PLC
09/09/202214h00Business WireLYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III TrialsNASDAQ:AZNAstraZeneca PLC
06/09/202212h14Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
06/09/202212h06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
05/09/202213h00Business WireIMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract CancerNASDAQ:AZNAstraZeneca PLC
05/09/202208h55Dow Jones NewsAstraZeneca Says Forxiga Approved in China for Chronic Kidney DiseaseNASDAQ:AZNAstraZeneca PLC
05/09/202208h49Dow Jones NewsAstraZeneca's Imfinzi Plus Chemotherapy Approved by FDA to Treat Advanced Biliary Tract CancerNASDAQ:AZNAstraZeneca PLC
30/08/202214h59Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
30/08/202214h50Dow Jones NewsAstraZeneca's Evusheld Approved for Covid-19 Treatment in JapanNASDAQ:AZNAstraZeneca PLC
30/08/202212h24Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
30/08/202212h12Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
27/08/202216h59Business WireNew data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failureNASDAQ:AZNAstraZeneca PLC
27/08/202216h36Business WireFARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trialNASDAQ:AZNAstraZeneca PLC
26/08/202200h09Dow Jones NewsADRs End Higher; Sony, Micro Focus Trade ActivelyNASDAQ:AZNAstraZeneca PLC
25/08/202212h47Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
25/08/202212h32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

CCOM
US100
US Tech 100
TG
MBG
MercedesBenz
PM
XAUUSD
Gold vs US Dollar
DBI
DAX
DAX
AMEX
SPY
SPDR S&P 500
FX
EURUSD
Euro vs US Dollar
TG
BAS
BASF
NYSE
MCD
McDonalds
TG
DBK
Deutsche Bank
NYSE
XOM
Exxon Mobil
USOTC
RHHBY
Roche (QX)
COIN
ETHUSD
Ethereum
TG
RHM
Rheinmetall
TG
432
Arbor Metals
TG
NOV
Novo Nordisk
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten